Just over 3 months into the vaccine roll out in the U.S., on March 20, 2021, Pfizer updated their original clinical trial mRNA vaccine protocol to include a new assessment criteria for a third dose (booster). “In order to describe the boostability of BNT162… against emerging SARS-CoV-2 VOCs, an additional dose of BNT162b2 will be given to Phase 1 participants approximately 6 to 12 months after their second dose…” [1, 2]
The mRNA vaccines were only assessed for reducing symptoms to COVID-19, and many vaccinated individuals are getting COVID-19, including severe symptoms – meaning the vaccines are “leaky“. The COVID-19 vaccines do not stop transmission or infection, and were never assessed for this, they were assessed on symptoms.
On April 1st, 2021 Pfizer then added “and potentially a fourth dose of prototype BNT162b2VOC (BNT162b2s01, based upon the South African variant and hereafter referred to as BNT162b2SA).”
Are the mRNA synthetic codes in these “vaccines” being altered? Is that what the “b1”, “b2” “b2SA” etc mean? This appears to be setting the stage for boosters every 6 months with a “new” synthetic mRNA code.